Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Can Accendra Health regain NYSE compliance before its April 2027 deadline?

Accendra Health faces a six-month NYSE deadline after ACH stock falls below $1. Examine reverse split options, debt and recovery risks.

Read More
Editorial infographic illustrating ALYFTREK’s reported pancreatic function gains in young children with cystic fibrosis, featuring a medical body diagram highlighting the pancreas, clinical charts and pediatric treatment imagery, with emphasis on potential implications for future care.
Pharma & Biotech

Vertex ALYFTREK data show pancreatic function recovery in young children with cystic fibrosis

Vertex reports pancreatic function gains with ALYFTREK in young children with cystic fibrosis. See what the results mean for future treatment.

Read More
Editorial infographic highlighting Seaport Therapeutics’ GlyphAgo, with laboratory imagery, capsule medication, a liver graphic and a bioavailability chart, showing 6.8-fold higher bioavailability, advancing anxiety trials and the still-unproven potential to reduce liver risks.
Pharma & Biotech

Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test

Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.

Read More
Editorial infographic illustrating Affinia Therapeutics’ AFTX-201 BAG3 heart gene therapy programme, featuring an anatomical heart, DNA strands and clinical research imagery, with highlights on the 22-patient trial, promising animal results and unproven human safety and efficacy.
Pharma & Biotech

Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026

Affinia advances AFTX-201 into a 22-patient BAG3 heart gene therapy trial after promising animal results. Human safety and efficacy remain unproven.

Read More
Editorial infographic highlighting Medincell’s second FDA-approved drug, Weltruza, featuring an injectable medicine, FDA approval symbol, U.S. launch map and graphics illustrating clinical evidence, royalty potential and commercial outlook.
Pharma & Biotech

Can Weltruza become Medincell’s next growth driver after Uzedy commercial success?

Medincell gains a second FDA-approved drug as Teva prepares Weltruza's U.S. launch. See the clinical evidence, royalties and commercial outlook.

Read More
Editorial infographic showing Oncomatryx’s OMTX305 in a tumor microenvironment, with immune T cells attacking cancer tissue and tumor-supporting fibroblasts, highlighting preclinical anti-tumor activity and unresolved clinical translation questions.
Pharma & Biotech

Can Oncomatryx OMTX305 overcome immune resistance in solid tumors?

Oncomatryx OMTX305 activates T cells and destroys tumor-supporting fibroblasts in preclinical cancer models. Examine the findings and limitations.

Read More
Editorial infographic illustrating GSK’s expanded AI drug discovery collaboration with Chai Discovery, featuring molecular protein-binding visuals, wet-lab testing, and key highlights on early binding success and unproven clinical and commercial outcomes.
Pharma & Biotech

Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold

GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.

Read More
Viz.ai’s HCM data push shows why cardiac AI is shifting from detection to care coordination
Pharma & Biotech

Secretome Therapeutics advances regenerative heart failure research with STM-01 trial data

Secretome Therapeutics reports early STM-01 safety data in 10 HFpEF patients, but unproven efficacy leaves bigger questions for future trials.

Read More
Pharma & Biotech

GlyphAgo boosted drug bioavailability 6.8-fold. Can Seaport solve agomelatine’s liver safety challenge?

Seaport's GlyphAgo improved agomelatine exposure in Phase 1. New Phase 2 trials will test efficacy, liver safety and anxiety outcomes.

Read More
Pharma & Biotech

Verda Healthcare joins forces with AstranaCare in two states, but how much growth can the deal deliver?

Verda Healthcare partners with AstranaCare in Texas and Arizona ahead of Medicare enrollment. Discover the network and growth implications.

Read More